BiotechTube
Scanogen

Scanogen

Baltimore, United States· Est.
scanogen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Scanogen is a private, pre-revenue diagnostics company pioneering a rapid, culture-free solution for sepsis diagnosis. Its SMART-ID BSI Assay, which has received FDA Breakthrough Device designation, aims to identify pathogens directly from whole blood in two hours, a dramatic improvement over the 1-2 day standard of blood cultures. The company's S1 Instrument is a modular, benchtop system designed for near-patient use in emergency departments and hospital labs. If successful, Scanogen's technology could significantly improve sepsis outcomes, reduce hospital costs, and combat antimicrobial resistance.

Infectious DiseaseSepsis

Technology Platform

SMART (Single Molecule And Rapid Tethering) technology for direct-from-whole-blood pathogen identification without culture.

Opportunities

The massive clinical and economic burden of sepsis creates a urgent need for rapid diagnostics.
FDA Breakthrough Device status accelerates regulatory pathway and validates clinical potential.
The point-of-care S1 system offers a key workflow advantage over central lab tests.

Risk Factors

Regulatory approval for a novel diagnostic is uncertain despite Breakthrough status.
Facing competition from larger, established diagnostics companies.
Commercial success depends on proving cost-effectiveness and changing entrenched hospital workflows.

Competitive Landscape

Competitors include large diagnostics firms (bioMerieux/BioFire, Luminex, Becton Dickinson) and smaller specialists (T2 Biosystems) developing rapid molecular and phenotypic tests for sepsis. Scanogen competes on its direct-from-whole-blood, two-hour, point-of-care claim.

More companies in Diagnostics & Precision Medicine →More companies in United States →